Oxford Biomedica (LON:OXB) Stock Breaks Below Two Hundred Day Moving Average - What's Next?

Key Points

• Oxford Biomedica shares fell below their 200-day moving average, trading as low as GBX 509 and last changing hands at GBX 509.67, compared with a 200-day average of GBX 570.92.
• Analysts maintain a generally positive outlook, with four Buy ratings and one Hold rating, an overall “Moderate Buy” consensus, and an average price target of GBX 580.85.
• The company reported a quarterly loss of GBX 30.39 per share, alongside negative profitability metrics; however, insider Roch Doliveux purchased 20,250 shares at GBX 505 each.

Oxford Biomedica plc (LON:OXB - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 570.92 and traded as low as GBX 509. Oxford Biomedica shares last traded at GBX 509.67, with a volume of 347,118 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Royal Bank Of Canada restated an "outperform" rating and set a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, Oxford Biomedica currently has an average rating of "Moderate Buy" and a consensus target price of GBX 580.85.

Oxford Biomedica Stock Performance

The company's fifty day simple moving average is GBX 499.47 and its 200 day simple moving average is GBX 570.92. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08. The stock has a market capitalization of £616.94 million, a P/E ratio of -18.93 and a beta of 1.09.

Oxford Biomedica (LON:OXB - Get Free Report) last released its quarterly earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. As a group, sell-side analysts forecast that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of the firm's stock in a transaction on Wednesday, September 23rd. The shares were acquired at an average cost of GBX 505 per share, for a total transaction of £102,262.50. 43.30% of the stock is currently owned by insiders.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.